Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) FCF Margin: 2011-2025

Historic FCF Margin for Iovance Biotherapeutics (IOVA) over the last 4 years, with Sep 2025 value amounting to -132.75%.

  • Iovance Biotherapeutics' FCF Margin fell 2813.00% to -132.75% in Q3 2025 from the same period last year, while for Sep 2025 it was -140.50%, marking a year-over-year increase of 27122.00%. This contributed to the annual value of -221.90% for FY2024, which is 3208340.00% up from last year.
  • As of Q3 2025, Iovance Biotherapeutics' FCF Margin stood at -132.75%, which was down 6.25% from -124.94% recorded in Q2 2025.
  • Over the past 5 years, Iovance Biotherapeutics' FCF Margin peaked at -104.62% during Q3 2024, and registered a low of -42,587.82% during Q2 2023.
  • For the 3-year period, Iovance Biotherapeutics' FCF Margin averaged around -9,812.54%, with its median value being -270.34% (2025).
  • Its FCF Margin has fluctuated over the past 5 years, first spiked by 4,226,996bps in 2024, then slumped by 2,813bps in 2025.
  • Iovance Biotherapeutics' FCF Margin (Quarterly) stood at -18,153.32% in 2023, then surged by 1,804,817bps to -105.15% in 2024, then slumped by 2,813bps to -132.75% in 2025.
  • Its last three reported values are -132.75% in Q3 2025, -124.94% for Q2 2025, and -222.83% during Q1 2025.